-
Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
30 Apr 2025 12:00 GMT
… ”), which commercializes Bentrio®, a drug free, preservative free nasal spray … US dollars. About Altamira Therapeutics Altamira Therapeutics (OTCQB:CYTOF) is developing … including siRNA, mRNA and circRNA, and made available to pharma or biotech companies …
-
Anti-inflammatory drug can prevent and alleviate periodontal tissue damage
29 Apr 2025 01:59 GMT
… that removes damaged mitochondria. The drug achieves this through regulation of … . When TUFM was silenced using siRNA, DMF lost its protective effects …
-
Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE® Platform at the American Society of Gene and Cell Therapy Annual Meeting
28 Apr 2025 20:40 GMT
… expression of mRNA or siRNA. These capabilities become … where precise and variable genetic control is needed … as follows:
Title: Drug-responsive domains coupled with … Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company …
-
Optimizing siRNA Therapeutics: Addressing Manufacturing Complexities
23 Apr 2025 03:43 GMT
… powerful gene-silencing mechanism. Breakthroughs in drug delivery, chemistry, and manufacturing have propelled siRNA therapeutics … , dermatology, and rare genetic diseases. Notably, multi-targeting siRNA therapies offer a …
-
Chinese IND clearance for Rona′s AGT-targeting siRNA drug for hypertension
25 Apr 2025 20:58 GMT
Cardiovascular
Rona Therapeutics Co. Ltd. has obtained IND … -1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) for hypertension …
-
Tariffs Won't Stop Drug-Candidate Licensing From China Biotechs
23 Apr 2025 17:29 GMT
… snap up Chinese biotechs’ efforts, and they are “importing” drug candidates to … large pharma leveraging small interfering RNA (siRNA) and RNA technology for targeted therapeutics … discussion.
U.S.-based pharma and biotech are acquiring promising pipeline …
-
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Call Transcript
30 Apr 2025 12:29 GMT
… profile consistent with the individual drugs, supporting further development. For odronextamab … to our Regeneron genetic medicines pipeline, our novel C5 siRNA and antibody … new agreement with FUJIFILM Diosynth Biotechnologies in North Carolina to invest …
-
Novel Antigen-Presenting Cell-Targeted Nanoparticles Enhance Split Vaccine Immunity Through Microneedles Inoculation
29 Apr 2025 23:38 GMT
… MNs), a novel transdermal drug delivery technology has emerged … was purchased from Beyotime Biotechnology. Sodium chloride was purchased … nanoparticles for macrophage-targeted siRNA delivery. ACS Appl … enhanced mechanical properties. Acta Pharma Sin. 2021;56( …
-
Thymosin β4 Regulates Tissue Inflammatory Response in Mouse Nonalcoholic Fatty Liver Disease by Promoting Macrophage M2-Type Polarization
29 Apr 2025 15:31 GMT
… reaction (qPCR) kit Shanghai Biotechnology Co. Ltd.; BCA quantification … was given normal diet without drug treatment. The model group … .01, compared with NC-siRNA.
Macrophage Depletion Impairs the … and opportunities in NASH drug development. Nat Med. 2023 …
-
Nano-Encapsulated Taro Lectin Can Cross an in vitro Blood-Brain Barrier, Induce Apoptosis and Autophagy and Inhibit the Migration of Human U-87 MG Glioblastoma Cells
29 Apr 2025 07:40 GMT
… present different molecular and genetic profiles) and infiltrative … of administering chemotherapeutic drugs glioblastoma locations beyond … Combination of B7H6-siRNA and temozolomide synergistically … Plant lectins in cancer therapeutics: targeting apoptosis and …
About
© 1995-2025